18 July 2016
Kuwait Life Sciences Company investment partner, New York based fund - New Leaf Ventue Partners recently invested in Basel based CRISPR Therapeutics as part of the firms 38 mn USD Series B round. CRISPR Therapeutics has now raised over 127 mn USD since its founding in 2013.
KLSC had identified CRISPR as a global and leading breakthrough technology in early 2015 and is currently working closely as part of a Public-Private consortium to transfer such novel technologies as part of the National Genome Center of Kuwait platform project.
Clustered Regularly Interspaced Short Palindromic Repeats - CRISPR(pronounced crisper) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid. The CRISPR interference technique has many potential applications, including altering the germline of humans, animals, and food crops. Most recently, the use of CRISPR forgenome editing won approval for a revolutionary trial to fight cancer in humans where scientist from the University of Pennsylvania will edit the immune systems of 18 patients to target cancer cells more effectively. The experiment won approval from the Recombinant DNA Advisory Committee (RAC), a US federal ethics panel set up at the National Institutes of Health to review controversial experiments that change the human genome.
As part of it's mission to transfer the latest technologies in the life science industry to Kuwait. KLSC will be working closely with experts from across the globe to transfer the CRISPR technology to the Middle East and North Africa region. KLSC plans for CRISPR to be an integral part of the National Genome Center platform it is currently developing in Kuwait with various stakeholders from the public and private life sciences sector.
In addition to financing, CRISPR Therapeutics has also been ramping up the deals and late last year announced a tie-up with both Vertex and Bayer creating various join ventures to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease using CRISPR-Cas9 gene-editing technology.
Kuwait Life Sciences Company investment partner, New York based fund - New Leaf Ventue Partners recently invested in Basel based CRISPR Therapeutics as part of the firms 38 mn USD Series B round. CRISPR Therapeutics has now raised over 127 mn USD since its founding in 2013.
KLSC had identified CRISPR as a global and leading breakthrough technology in early 2015 and is currently working closely as part of a Public-Private consortium to transfer such novel technologies as part of the National Genome Center of Kuwait platform project.
Clustered Regularly Interspaced Short Palindromic Repeats - CRISPR(pronounced crisper) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid. The CRISPR interference technique has many potential applications, including altering the germline of humans, animals, and food crops. Most recently, the use of CRISPR forgenome editing won approval for a revolutionary trial to fight cancer in humans where scientist from the University of Pennsylvania will edit the immune systems of 18 patients to target cancer cells more effectively. The experiment won approval from the Recombinant DNA Advisory Committee (RAC), a US federal ethics panel set up at the National Institutes of Health to review controversial experiments that change the human genome.
As part of it's mission to transfer the latest technologies in the life science industry to Kuwait. KLSC will be working closely with experts from across the globe to transfer the CRISPR technology to the Middle East and North Africa region. KLSC plans for CRISPR to be an integral part of the National Genome Center platform it is currently developing in Kuwait with various stakeholders from the public and private life sciences sector.
In addition to financing, CRISPR Therapeutics has also been ramping up the deals and late last year announced a tie-up with both Vertex and Bayer creating various join ventures to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease using CRISPR-Cas9 gene-editing technology.
© Press Release 2016
